Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Biotec Pharmacon ASA
Woman and Man
Between 18 years
and 99 years
Biotec Pharmacon ASA
Update Il y a 4 ans
BIOTEC Pharmacon SBG-2-03 : Essai de phase 3 randomisé, en double aveugle avec placebo, évaluant l’efficacité et la tolérance du SBG (Soluble béta-1,3/1,6 glucan), pour traiter les mucites orales, chez des patients ayant un cancer de la tête et du cou traités par radiothérapie. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
L’objectif de cet essai est d’évaluer l’efficacité et la tolérance du béta-1,3/1,6 glucan sur la prévention de mucosite orale induite par la radiothérapie, chez des patients ayant un cancer de la tête...
Country
France
organs
Tête et cou
Specialty
Autres (cryothérapie, radiofréquence, homéopathie,...)
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Biotec Pharmacon ASA
Update Il y a 4 ans
A randomised, double-blind, placebo-controlled study to determine the efficacy of soluble beta-1,3/1,6-glucan in chronic foot ulcers in diabetes
To determine the effect of topically administered soluble beta-1,3/1,6-glucan (SBG) compared with that of placebo in chronic foot ulcers in diabetes.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Biotec Pharmacon ASA
Update Il y a 4 ans
A randomised, double-blind, placebo-controlled study to assess the efficacy and safety of soluble beta-1,3/1,6-glucan (SBG) in chronic foot ulcers in patients with diabetes
To compare the proportion of patients who have healing of their target ulcer within 8 weeks after starting topical treatment with SBG or placebo.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Biotec Pharmacon ASA
Update Il y a 4 ans
A randomized, double-blind, placebo-controlled, parallel-group phase III clinical study to assess the efficacy and safety of soluble beta 1,3/1,6 glucan (SBG) on oral mucositis in head and neck cancer patients undergoing radiation therapy with or without chemotherapy
To evaluate the efficacy and safety of SBG when administered from 1 day prior to 5 days after completion of radiotherapy.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Biotec Pharmacon ASA
Update Il y a 4 ans
A randomized, double-blind, placebo-controlled, parallel-group phase III clinical study to assess the efficacy and safety of soluble beta 1,3/1,6 glucan (SBG) on oral mucositis in head and neck cancer patients undergoing radiation therapy with or without chemotherapy
To evaluate the efficacy and safety of SBG when administered from 1 day prior to 5 days after completion of radiotherapy.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Biotec Pharmacon ASA
Update Il y a 4 ans
A phase I/II study to assess the effect of soluble beta-1,3/1,6-glucan in combination with standard therapy in patients with breast cancer
Define the clinical toxicity and assess the biologic effects of oral SBG when given to breast cancer patients undergoing standard chemo- and antibody treatment
Country
None
organs
None
Specialty
None
Closed trial
More information